Publications
This publication page was updated 2024-10-22. For the most up-to-date list of publications and links, please see NCBI My Bibliography.
Saint Louis University (2010-present)
63. Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice.
Ajiboye J, Teixeira JE, Gasonoo M, Mattice EB, Korwin-Mihavics B, Miller P, Cameron AC, Stebbins E, Campbell SD, Griggs DW, Spangenberg T, Meyers MJ, Huston CD. Nat Commun. 2024;15(1):8272. doi: 10.1038/s41467-024-52658-y.
Ajiboye J, Teixeira JE, Gasonoo M, Mattice EB, Korwin-Mihavics B, Miller P, Cameron AC, Stebbins E, Campbell SD, Griggs DW, Spangenberg T, Meyers MJ, Huston CD. Nat Commun. 2024;15(1):8272. doi: 10.1038/s41467-024-52658-y.
62. Synthesis and Antifungal Activity of Stereoisomers of Mefloquine Analogs.
Guin S, Alden KM, Krysan DJ, Meyers MJ. ACS Med Chem Lett. 2024;15(6):822-827. doi: 10.1021/acsmedchemlett.4c00031.
Guin S, Alden KM, Krysan DJ, Meyers MJ. ACS Med Chem Lett. 2024;15(6):822-827. doi: 10.1021/acsmedchemlett.4c00031.
61. Targeting CXCR4, VLA-4, and CXCR2 for hematopoietic stem cell mobilization.
Cancilla D, Rettig MP, Karpova D, Thakellapalli H, Singh M, Meyers MJ, Ruminski PG, Christ S, Chendamarai E, Gao F, Gehrs L, Ritchey JK, Prinsen M, DiPersio JF. Blood Adv. 2024;8(6):1379-1383. doi: 10.1182/bloodadvances.2023011653.
Cancilla D, Rettig MP, Karpova D, Thakellapalli H, Singh M, Meyers MJ, Ruminski PG, Christ S, Chendamarai E, Gao F, Gehrs L, Ritchey JK, Prinsen M, DiPersio JF. Blood Adv. 2024;8(6):1379-1383. doi: 10.1182/bloodadvances.2023011653.
60. Comparative chemical genomics in Babesia species identifies the alkaline phosphatase PhoD as a determinant of antiparasitic resistance.
Keroack CD, Elsworth B, Tennessen JA, Paul AS, Hua R, Ramirez-Ramirez L, Ye S, Moreira CK, Meyers MJ, Zarringhalam K, Duraisingh MT. Proc Natl Acad Sci U S A. 2024;121(9):e2312987121. doi: 10.1073/pnas.2312987121.
Keroack CD, Elsworth B, Tennessen JA, Paul AS, Hua R, Ramirez-Ramirez L, Ye S, Moreira CK, Meyers MJ, Zarringhalam K, Duraisingh MT. Proc Natl Acad Sci U S A. 2024;121(9):e2312987121. doi: 10.1073/pnas.2312987121.
59. The anti-cancer efficacy of a novel phenothiazine derivative is independent of dopamine and serotonin receptor inhibition.
Vanneste M, Venzke A, Guin S, Fuller AJ, Jezewski AJ, Beattie SR, Krysan DJ, Meyers MJ, Henry MD. Front Oncol. 2023;13:1295185. doi: 10.3389/fonc.2023.1295185.
Vanneste M, Venzke A, Guin S, Fuller AJ, Jezewski AJ, Beattie SR, Krysan DJ, Meyers MJ, Henry MD. Front Oncol. 2023;13:1295185. doi: 10.3389/fonc.2023.1295185.
58. Safe and effective treatments are needed for cryptosporidiosis, a truly neglected tropical disease.
Gilbert IH, Vinayak S, Striepen B, Manjunatha UH, Khalil IA, Van Voorhis WC, Cryptosporidiosis Therapeutics Advocacy Group CTAG. BMJ Glob Health. 2023;8(8). doi: 10.1136/bmjgh-2023-012540.
Gilbert IH, Vinayak S, Striepen B, Manjunatha UH, Khalil IA, Van Voorhis WC, Cryptosporidiosis Therapeutics Advocacy Group CTAG. BMJ Glob Health. 2023;8(8). doi: 10.1136/bmjgh-2023-012540.
57. CWHM-974 is a fluphenazine derivative with improved antifungal activity against Candida albicans due to reduced susceptibility to multidrug transporter-mediated resistance mechanisms.
Miron-Ocampo A, Beattie SR, Guin S, Conway T, Meyers MJ, Moye-Rowley WS, Krysan DJ. Antimicrob Agents Chemother. 2023;67(10):e0056723. doi: 10.1128/aac.00567-23.
Miron-Ocampo A, Beattie SR, Guin S, Conway T, Meyers MJ, Moye-Rowley WS, Krysan DJ. Antimicrob Agents Chemother. 2023;67(10):e0056723. doi: 10.1128/aac.00567-23.
56. MEPicides: α,β-unsaturated Fosmidomycin N-Acyl Analogs as Efficient Inhibitors of Plasmodium falciparum 1-Deoxy-d-xylulose-5-phosphate reductoisomerase.
Wang X, Edwards RL, Ball HS, Heidel KM, Brothers RC, Johnson C, Haymond A, Girma M, Dailey A, Roma JS, Boshoff HI, Osbourn DM, Meyers MJ, Couch RD, Odom John AR, Dowd CS. ACS Infect Dis. 2023;9(7):1387-1395. doi: 10.1021/acsinfecdis.3c00132.
Wang X, Edwards RL, Ball HS, Heidel KM, Brothers RC, Johnson C, Haymond A, Girma M, Dailey A, Roma JS, Boshoff HI, Osbourn DM, Meyers MJ, Couch RD, Odom John AR, Dowd CS. ACS Infect Dis. 2023;9(7):1387-1395. doi: 10.1021/acsinfecdis.3c00132.
55. Structure-Activity Relationship Studies of the Aryl Acetamide Triazolopyridazines against Cryptosporidium Reveals Remarkable Role of Fluorine.
Schubert TJ, Oboh E, Peek H, Philo E, Teixeira JE, Stebbins EE, Miller P, Oliva J, Sverdrup FM, Griggs DW, Huston CD, Meyers MJ. J Med Chem. 2023;66(12):7834-7848. doi: 10.1021/acs.jmedchem.3c00110.
Schubert TJ, Oboh E, Peek H, Philo E, Teixeira JE, Stebbins EE, Miller P, Oliva J, Sverdrup FM, Griggs DW, Huston CD, Meyers MJ. J Med Chem. 2023;66(12):7834-7848. doi: 10.1021/acs.jmedchem.3c00110.
54. Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.
Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ. Bioorg Med Chem. 2023 86:117295. doi: 10.1016/j.bmc.2023.117295
Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ. Bioorg Med Chem. 2023 86:117295. doi: 10.1016/j.bmc.2023.117295
53. Synthetic derivatives of the antifungal drug ciclopirox are active against herpes simplex virus 2.
Zangi M, Donald KA, Casals AG, Franson AD, Yu AJ, Marker EM, Woodson ME, Campbell SD, Mottaleb MA, Narayana Hajay Kumar TV, Reddy MS, Raghava Reddy LV, Sadhukhan SK, Griggs DW, Morrison LA, Meyers MJ. Eur. J. Med. Chem. 2022, 238:114443. doi.org/10.1016/j.ejmech.2022.114443
Zangi M, Donald KA, Casals AG, Franson AD, Yu AJ, Marker EM, Woodson ME, Campbell SD, Mottaleb MA, Narayana Hajay Kumar TV, Reddy MS, Raghava Reddy LV, Sadhukhan SK, Griggs DW, Morrison LA, Meyers MJ. Eur. J. Med. Chem. 2022, 238:114443. doi.org/10.1016/j.ejmech.2022.114443
52. Repurposing and optimization of drugs for discovery of novel antifungals.
Donlin MJ, Meyers MJ. Drug Discov. Today. 2022, 7:2008-2014. doi.org/10.1016/j.drudis.2022.04.021
Donlin MJ, Meyers MJ. Drug Discov. Today. 2022, 7:2008-2014. doi.org/10.1016/j.drudis.2022.04.021
51. Mechanism of Action of N-Acyl and N-Alkoxy Fosmidomycin Analogs: Mono- and Bisubstrate Inhibition of IspC from Plasmodium falciparum, a Causative Agent of Malaria.
Girma MB, Ball HS, Wang X, Brothers RC, Jackson ER, Meyers MJ, Dowd CS, Couch RD. ACS Omega. 2021, 6(42):27630-27639. doi: 10.1021/acsomega.1c01711.
Girma MB, Ball HS, Wang X, Brothers RC, Jackson ER, Meyers MJ, Dowd CS, Couch RD. ACS Omega. 2021, 6(42):27630-27639. doi: 10.1021/acsomega.1c01711.
50. Efficient Inhibition of Hepatitis B Virus (HBV) Replication and cccDNA Formation by HBV Ribonuclease H Inhibitors during Infection.
Chauhan R, Li Q, Woodson ME, Gasonoo M, Meyers MJ, Tavis JE. Antimicrob Agents Chemother. 2021, 65(12):e0146021. doi: 10.1128/AAC.01460-21.
Chauhan R, Li Q, Woodson ME, Gasonoo M, Meyers MJ, Tavis JE. Antimicrob Agents Chemother. 2021, 65(12):e0146021. doi: 10.1128/AAC.01460-21.
49. Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin.
Oboh E, Schubert TJ, Teixeira JE, Stebbins EE, Miller P, Philo E, Thakellapalli H, Campbell SD, Griggs DW, Huston CD*, Meyers MJ*. J. Med. Chem. 2021, ASAP. doi.org/10.1021/acs.jmedchem.1c01136.
Oboh E, Schubert TJ, Teixeira JE, Stebbins EE, Miller P, Philo E, Thakellapalli H, Campbell SD, Griggs DW, Huston CD*, Meyers MJ*. J. Med. Chem. 2021, ASAP. doi.org/10.1021/acs.jmedchem.1c01136.
48. Synthetic Derivatives of Ciclopirox are Effective Inhibitors of Cryptococcus neoformans.
Lin J, Zangi M, Kumar TVNH, Shakar Reddy M, Reddy LVR, Sadhukhan SK, Bradley DP, Moreira-Walsh B, Edwards TC, O'Dea AT, Tavis JE, Meyers MJ, Donlin MJ. ACS Omega 2021, 6(12):8477-8487. doi: 10.1021/acsomega.1c00273.
Lin J, Zangi M, Kumar TVNH, Shakar Reddy M, Reddy LVR, Sadhukhan SK, Bradley DP, Moreira-Walsh B, Edwards TC, O'Dea AT, Tavis JE, Meyers MJ, Donlin MJ. ACS Omega 2021, 6(12):8477-8487. doi: 10.1021/acsomega.1c00273.
47. Identification of 4-Amino-Thieno[2,3-d]Pyrimidines as QcrB Inhibitors in Mycobacterium tuberculosis. Harrison GA, Mayer Bridwell AE, Singh M, Jayaraman K, Weiss LA, Kinsella RL, Aneke JS, Flentie K, Schene ME, Gaggioli M, Solomon SD, Wildman SA, Meyers MJ, Stallings CL. mSphere 2019 Sep 11;4(5). doi: 10.1128/mSphere.00606-19.
46. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy. Oliva J, Galasinski S, Richey A, Campbell AE, Meyers MJ, Modi N, Zhong JW, Tawil R, Tapscott SJ, Sverdrup FM. J Pharmacol Exp Ther. 2019, 370(2):219-230. doi: 10.1124/jpet.119.259663.
45. 4-Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2-Aryl-N-(4-arylpyrrolidin-3-yl)acetamides. Meyers MJ, Liu J, Liu Z, Ma H, Dai L, Adah D, Zhao S, Li X, Liu X, Lu Y, Huang Y, Tu Z, Chen X, Tortorella MD. ACS Med Chem Lett. 2019, 10(6):966-971. doi: 10.1021/acsmedchemlett.9b00123.
44. Targeting VLA4 integrin and CXCR2 mobilizes serially repopulating hematopoietic stem cells. Karpova D, Rettig MP, Ritchey J, Cancilla D, Christ S, Gehrs L, Chendamarai E, Evbuomwan MO, Holt M, Zhang J, Abou-Ezzi G, Celik H, Wiercinska E, Yang W, Gao F, Eissenberg LG, Heier RF, Arnett SD, Meyers MJ, Prinsen MJ, Griggs DW, Trumpp A, Ruminski PG, Morrow DM, Bonig HB, Link DC, DiPersio JF. J Clin Invest. 2019130:2745-2759. doi: 10.1172/JCI124738.
43. 4-Aryl Pyrrolidines as a Novel Class of Orally Efficacious Antimalarial Agents. Part 1: Evaluation of 4-Aryl- N-benzylpyrrolidine-3-carboxamides. Meyers MJ, Liu J, Xu J, Leng F, Guan J, Liu Z, McNitt SA, Qin L, Dai L, Ma H, Adah D, Zhao S, Li X, Polino AJ, Nasamu AS, Goldberg DE, Liu X, Lu Y, Tu Z, Chen X, Tortorella MD. J Med Chem. 2019, 62(7):3503-3512. doi: 10.1021/acs.jmedchem.8b01972.
42. Endonuclease Activity Inhibition of the NS1 Protein of Parvovirus B19 as a Novel Target for Antiviral Drug Development. Xu P, Ganaie SS, Wang X, Wang Z, Kleiboeker S, Horton NC, Heier RF, Meyers MJ, Tavis JE, Qiu J. Antimicrob Agents Chemother. 2019, 63(3). doi: 10.1128/AAC.01879-18.
41. Synthesis and Evaluation of Troponoids as a New Class of Antibiotics. Cao F, Orth C, Donlin MJ, Adegboyega P, Meyers MJ, Murelli RP, Elagawany M, Elgendy B, Tavis JE. ACS Omega. 2018, 3(11):15125-15133. doi: 10.1021/acsomega.8b01754.
40. MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria. Wang X, Edwards RL, Ball H, Johnson C, Haymond A, Girma M, Manikkam M, Brothers RC, McKay KT, Arnett SD, Osbourn DM, Alvarez S, Boshoff HI, Meyers MJ, Couch RD, Odom John AR, Dowd CS. J Med Chem. 2018, 61(19):8847-8858. doi: 10.1021/acs.jmedchem.8b01026.
38. Antifungal Phenothiazines: Optimization, Characterization of Mechanism, and Modulation of Neuroreceptor Activity. Montoya MC, DiDone L, Heier RF, Meyers MJ, Krysan DJ. ACS Infect Dis. 2018, 4(4):499-507. doi: 10.1021/acsinfecdis.7b00157.
37. A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open-Access Malaria Box. Jumani RS, Bessoff K, Love MS, Miller P, Stebbins EE, Teixeira JE, Campbell MA, Meyers MJ, Zambriski JA, Nunez V, Woods AK, McNamara CW, Huston CD. Antimicrob Agents Chemother. 2018, 62(4). doi: 10.1128/AAC.01505-17.
36. Chemical Approaches to Inhibiting the Hepatitis B Virus Ribonuclease H. Tavis JE, Zoidis G, Meyers MJ, Murelli RP. ACS Infect Dis. 2018, doi: 10.1021/acsinfecdis.8b00045.
35. Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model. Stebbins E, Jumani RS, Klopfer C, Barlow J, Miller P, Campbell MA, Meyers MJ, Griggs DW, Huston CD. PLoS Negl Trop Dis. 2018, 12(1):e0006183. doi: 10.1371/journal.pntd.0006183.
34. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion. Nasamu AS, Glushakova S, Russo I, Vaupel B, Oksman A, Kim AS, Fremont DH, Tolia N, Beck JR, Meyers MJ, Niles JC, Zimmerberg J, Goldberg DE. Science. 2017, 358(6362):518-522. doi: 10.1126/science.aan1478.
33. The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis. Lee S, Harwood M, Girouard D, Meyers MJ, Campbell MA, Beamer G, Tzipori S. PLoS One. 2017, 12(10):e0185906. doi: 10.1371/journal.pone.0185906.
32. Rev-Erb co-regulates muscle regeneration via tethered interaction with the NF-Y cistrome. Welch RD, Guo C, Sengupta M, Carpenter KJ, Stephens NA, Arnett SA, Meyers MJ, Sparks LM, Smith SR, Zhang J, Burris TP, Flaveny CA. Mol Metab.2017,6(7):703-714. doi: 10.1016/j.molmet.2017.05.001.
31. Troponoids Can Inhibit Growth of the Human Fungal Pathogen Cryptococcus neoformans. Donlin MJ, Zunica A, Lipnicky A, Garimallaprabhakaran AK, Berkowitz AJ, Grigoryan A, Meyers MJ, Tavis JE, Murelli RP. Antimicrob Agents Chemother. 2017, 61(4). doi: 10.1128/AAC.02574-16.
30. Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors. Lu G, Villa JA, Donlin MJ, Edwards TC, Cheng X, Heier RF, Meyers MJ, Tavis JE. Antiviral Res. 2016, 135:24-30. doi: 10.1016/j.antiviral.2016.09.009.
29. Synthesis, antimalarial properties and 2D-QSAR studies of novel triazole-quinine conjugates. Faidallah HM, Panda SS, Serrano JC, Girgis AS, Khan KA, Alamry KA, Therathanakorn T, Meyers MJ, Sverdrup FM, Eickhoff CS, Getchell SG, Katritzky AR. Bioorg Med Chem. 2016, 24(16):3527-39. doi: 10.1016/j.bmc.2016.05.060.
28. Pharmacologic Comparison of Clinical Neutral Endopeptidase Inhibitors in a Rat Model of Acute Secretory Diarrhea. Griggs DW, Prinsen MJ, Oliva J, Campbell MA, Arnett SD, Tajfirouz D, Ruminski PG, Yu Y, Bond BR, Ji Y, Neckermann G, Choy RK, de Hostos E, Meyers MJ. J Pharmacol Exp Ther. 2016357(2):423-31. doi: 10.1124/jpet.115.231167.
27. Characterization of the C-Terminal Nuclease Domain of Herpes Simplex Virus pUL15 as a Target of Nucleotidyltransferase Inhibitors. Masaoka T, Zhao H, Hirsch DR, D'Erasmo MP, Meck C, Varnado B, Gupta A, Meyers MJ, Baines J, Beutler JA, Murelli RP, Tang L, Le Grice SF. Biochemistry. 2016, 55(5):809-19. doi: 10.1021/acs.biochem.5b01254.
26. Evaluation of spiropiperidine hydantoins as a novel class of antimalarial agents. Meyers MJ, Anderson EJ, McNitt SA, Krenning TM, Singh M, Xu J, Zeng W, Qin L, Xu W, Zhao S, Qin L, Eickhoff CS, Oliva J, Campbell MA, Arnett SD, Prinsen MJ, Griggs DW, Ruminski PG, Goldberg DE, Ding K, Liu X, Tu Z, Tortorella MD, Sverdrup FM, Chen X. Bioorg Med Chem. 2015, 23(16):5144-50. doi: 10.1016/j.bmc.2015.02.050.
25. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Lu G, Lomonosova E, Cheng X, Moran EA, Meyers MJ, Le Grice SF, Thomas CJ, Jiang JK, Meck C, Hirsch DR, D'Erasmo MP, Suyabatmaz DM, Murelli RP, Tavis JE. Antimicrob Agents Chemother. 2015, 59(2):1070-9. doi: 10.1128/AAC.04617-14.
24. Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Cai CW, Lomonosova E, Moran EA, Cheng X, Patel KB, Bailly F, Cotelle P, Meyers MJ, Tavis JE. Antiviral Res.2014, 108:48-55. doi: 10.1016/j.antiviral.2014.05.007.
22. Evaluation of aminohydantoins as a novel class of antimalarial agents. Meyers MJ, Tortorella MD, Xu J, Qin L, He Z, Lang X, Zeng W, Xu W, Qin L, Prinsen MJ, Sverdrup FM, Eickhoff CS, Griggs DW, Oliva J, Ruminski PG, Jacobsen EJ, Campbell MA, Wood DC, Goldberg DE, Liu X, Lu Y, Lu X, Tu Z, Lu X, Ding K, Chen X. ACS Med Chem Lett. 2014, 5(1):89-93. doi: 10.1021/ml400412x.
21. Synthesis and antimalarial bioassay of quinine - peptide conjugates. Panda SS, Ibrahim MA, Küçükbay H, Meyers MJ, Sverdrup FM, El-Feky SA, Katritzky AR. Chem Biol Drug Des. 2013, 82(4):361-6. doi: 10.1111/cbdd.12134.
20. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes. Tavis JE, Cheng X, Hu Y, Totten M, Cao F, Michailidis E, Aurora R, Meyers MJ, Jacobsen EJ, Parniak MA, Sarafianos SG. PLoS Pathog. 2013, 9(1):e1003125. doi: 10.1371/journal.ppat.1003125.
19. Quinine bis-conjugates with quinolone antibiotics and peptides: synthesis and antimalarial bioassay. Panda SS, Bajaj K, Meyers MJ, Sverdrup FM, Katritzky AR. Org Biomol Chem. 2012, 10(45):8985-93. doi: 10.1039/c2ob26439k.
18. Recent advances in plasmepsin medicinal chemistry and implications for future antimalarial drug discovery efforts. Meyers MJ, Goldberg DE. Curr Top Med Chem. 2012, 12(5):445-55.
17. Editorial: the medicinal chemistry of novel approaches for the treatment of malaria. Meyers MJ. Curr Top Med Chem.2012, 12(5):371-2.
Pfizer Career (2000-2010)
39. Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist. Schnute ME, Wennerstål M, Alley J, Bengtsson M, Blinn JR, Bolten CW, Braden T, Bonn T, Carlsson B, Caspers N, Chen M, Choi C, Collis LP, Crouse K, Färnegårdh M, Fennell KF, Fish S, Flick AC, Goos-Nilsson A, Gullberg H, Harris PK, Heasley SE, Hegen M, Hromockyj AE, Hu X, Husman B, Janosik T, Jones P, Kaila N, Kallin E, Kauppi B, Kiefer JR, Knafels J, Koehler K, Kruger L, Kurumbail RG, Kyne RE Jr, Li W, Löfstedt J, Long SA, Menard CA, Mente S, Messing D, Meyers MJ, Napierata L, Nöteberg D, Nuhant P, Pelc MJ, Prinsen MJ, Rhönnstad P, Backström-Rydin E, Sandberg J, Sandström M, Shah F, Sjöberg M, Sundell A, Taylor AP, Thorarensen A, Trujillo JI, Trzupek JD, Unwalla R, Vajdos FF, Weinberg RA, Wood DC, Xing L, Zamaratski E, Zapf CW, Zhao Y, Wilhelmsson A, Berstein G. J Med Chem. 2018, 61(23):10415-10439. doi: 10.1021/acs.jmedchem.8b00392.
23. Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. Casimiro-Garcia A, Piotrowski DW, Ambler C, Arhancet GB, Banker ME, Banks T, Boustany-Kari CM, Cai C, Chen X, Eudy R, Hepworth D, Hulford CA, Jennings SM, Loria PM, Meyers MJ, Petersen DN, Raheja NK, Sammons M, She L, Song K, Vrieze D, Wei L. J Med Chem.2014, 57(10):4273-88. doi: 10.1021/jm500206r.
16. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds. Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Walker MC, Schweitzer BA, Madsen HM, Tenbrink RE, McDonald J, Smith SE, Foltin S, Beidler D, Thorarensen A. Bioorg Med Chem Lett. 2011, 21(21):6538-44. doi: 10.1016/j.bmcl.2011.08.055.
15. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain. Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Schweitzer BA, Wilcox MV, McDonald J, Smith SE, Foltin S, Rumsey J, Yang YS, Walker MC, Kamtekar S, Beidler D, Thorarensen A. Bioorg Med Chem Lett. 2011, 21(21):6545-53. doi: 10.1016/j.bmcl.2011.08.048.
14. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. Meyers MJ, Arhancet GB, Hockerman SL, Chen X, Long SA, Mahoney MW, Rico JR, Garland DJ, Blinn JR, Collins JT, Yang S, Huang HC, McGee KF, Wendling JM, Dietz JD, Payne MA, Homer BL, Heron MI, Reitz DB, Hu X. J Med Chem. 2010, 53(16):5979-6002. doi: 10.1021/jm100505n.
13. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. Mourey RJ, Burnette BL, Brustkern SJ, Daniels JS, Hirsch JL, Hood WF, Meyers MJ, Mnich SJ, Pierce BS, Saabye MJ, Schindler JF, South SA, Webb EG, Zhang J, Anderson DR. J Pharmacol Exp Ther. 2010, 333(3):797-807. doi: 10.1124/jpet.110.166173.
12. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A. Bioorg Med Chem Lett. 2010,20(5):1543-7. doi: 10.1016/j.bmcl.2010.01.078.
11. Synthesis of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate. Meyers MJ, Muizebelt I, van Wiltenburg J, Brown DL, Thorarensen A. Org Lett. 2009, 11(16):3523-5. doi: 10.1021/ol901325s.
10. Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency. Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ, Parikh MD. Bioorg Med Chem Lett.2009, 19(16):4882-4. doi: 10.1016/j.bmcl.2009.02.017.
9. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency. Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ. Bioorg Med Chem Lett. 2009, 19(16):4878-81. doi: 10.1016/j.bmcl.2009.02.015.
8. Novel tetrahydro-beta-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Trujillo JI, Meyers MJ, Anderson DR, Hegde S, Mahoney MW, Vernier WF, Buchler IP, Wu KK, Yang S, Hartmann SJ, Reitz DB. Bioorg Med Chem Lett. 2007, 17(16):4657-63. doi: 10.1016/j.bmcl.2007.05.070.
7. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ. J Med Chem. 2007, 50(11):2647-54. doi: 10.1021/jm0611004.
6. Non-steroidal Mineralocorticoid Receptor Antagonists. Meyers MJ, Xiao H. ExpertOpin Therapeutic Patents. 2007, 17:17-23.
23. Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist. Casimiro-Garcia A, Piotrowski DW, Ambler C, Arhancet GB, Banker ME, Banks T, Boustany-Kari CM, Cai C, Chen X, Eudy R, Hepworth D, Hulford CA, Jennings SM, Loria PM, Meyers MJ, Petersen DN, Raheja NK, Sammons M, She L, Song K, Vrieze D, Wei L. J Med Chem.2014, 57(10):4273-88. doi: 10.1021/jm500206r.
16. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds. Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Walker MC, Schweitzer BA, Madsen HM, Tenbrink RE, McDonald J, Smith SE, Foltin S, Beidler D, Thorarensen A. Bioorg Med Chem Lett. 2011, 21(21):6538-44. doi: 10.1016/j.bmcl.2011.08.055.
15. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain. Meyers MJ, Long SA, Pelc MJ, Wang JL, Bowen SJ, Schweitzer BA, Wilcox MV, McDonald J, Smith SE, Foltin S, Rumsey J, Yang YS, Walker MC, Kamtekar S, Beidler D, Thorarensen A. Bioorg Med Chem Lett. 2011, 21(21):6545-53. doi: 10.1016/j.bmcl.2011.08.048.
14. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. Meyers MJ, Arhancet GB, Hockerman SL, Chen X, Long SA, Mahoney MW, Rico JR, Garland DJ, Blinn JR, Collins JT, Yang S, Huang HC, McGee KF, Wendling JM, Dietz JD, Payne MA, Homer BL, Heron MI, Reitz DB, Hu X. J Med Chem. 2010, 53(16):5979-6002. doi: 10.1021/jm100505n.
13. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor alpha production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. Mourey RJ, Burnette BL, Brustkern SJ, Daniels JS, Hirsch JL, Hood WF, Meyers MJ, Mnich SJ, Pierce BS, Saabye MJ, Schindler JF, South SA, Webb EG, Zhang J, Anderson DR. J Pharmacol Exp Ther. 2010, 333(3):797-807. doi: 10.1124/jpet.110.166173.
12. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. Meyers MJ, Pelc M, Kamtekar S, Day J, Poda GI, Hall MK, Michener ML, Reitz BA, Mathis KJ, Pierce BS, Parikh MD, Mischke DA, Long SA, Parlow JJ, Anderson DR, Thorarensen A. Bioorg Med Chem Lett. 2010,20(5):1543-7. doi: 10.1016/j.bmcl.2010.01.078.
11. Synthesis of tert-butyl 6-oxo-2-azaspiro[3.3]heptane-2-carboxylate. Meyers MJ, Muizebelt I, van Wiltenburg J, Brown DL, Thorarensen A. Org Lett. 2009, 11(16):3523-5. doi: 10.1021/ol901325s.
10. Benzothiophene inhibitors of MK2. Part 2: improvements in kinase selectivity and cell potency. Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ, Parikh MD. Bioorg Med Chem Lett.2009, 19(16):4882-4. doi: 10.1016/j.bmcl.2009.02.017.
9. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency. Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ. Bioorg Med Chem Lett. 2009, 19(16):4878-81. doi: 10.1016/j.bmcl.2009.02.015.
8. Novel tetrahydro-beta-carboline-1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Trujillo JI, Meyers MJ, Anderson DR, Hegde S, Mahoney MW, Vernier WF, Buchler IP, Wu KK, Yang S, Hartmann SJ, Reitz DB. Bioorg Med Chem Lett. 2007, 17(16):4657-63. doi: 10.1016/j.bmcl.2007.05.070.
7. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ. J Med Chem. 2007, 50(11):2647-54. doi: 10.1021/jm0611004.
6. Non-steroidal Mineralocorticoid Receptor Antagonists. Meyers MJ, Xiao H. ExpertOpin Therapeutic Patents. 2007, 17:17-23.
Graduate School (1996-2000)
5. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL. Nat Struct Biol. 2002, 9(5):359-64. doi: 10.1038/nsb787.
4. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues.Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, Katzenellenbogen JA. J Med Chem. 2001, 44(24):4230-51. doi: 10.1021/jm010254a.
3. Estrogen receptor subtype-selective ligands: asymmetric synthesis and biological evaluation of cis- and trans-5,11-dialkyl- 5,6,11, 12-tetrahydrochrysenes. Meyers MJ, Sun J, Carlson KE, Katzenellenbogen BS, Katzenellenbogen JA. J Med Chem. 1999, 42(13):2456-68. doi: 10.1021/jm990101b.
2. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS. Endocrinology. 1999, 140(2):800-4. doi: 10.1210/endo.140.2.6480.
1. Facile synthesis of high affinity styrylpyridine systems as inherently fluorescent ligands for the estrogen receptor. Meyers MJ, Carlson KE, Katzenellenbogen JA. Bioorg Med Chem Lett. 1998, 8(24):3589-94.
